Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Clinical
  • Published:

Measurement of serum total and free prostate-specific antigen in women with colorectal carcinoma

British Journal of Cancer volume 86, pages 203–206 (2002)Cite this article

Abstract

We investigated the diagnostic value and the relationship with clinicopathological features of total and free prostate-specific antigen by measuring the concentrations of these markers in the sera of 75 women with colorectal carcinoma and in 30 healthy women. Measurements were performed by immunoradiometric assay which utilizes monoclonal and polyclonal anti-prostate-specific antigen antibodies; the lowest detection level for both markers was 0.01 ng ml−1. Free prostate-specific antigen levels were significantly higher in women with colorectal carcinoma than healthy women (P=0.006). The percentage of free prostate-specific antigen predominant (free prostate-specific antigen/total prostate-specific antigen >50%) subjects was 20% in colorectal carcinoma patients and 3.3% in healthy women (P=0.035). Cut-off values were 0.34 ng ml−1 for total prostate-specific antigen and 0.01 ng ml−1 for free prostate-specific antigen. In women with colorectal carcinoma, total prostate-specific antigen positivity was 20% and free prostate-specific antigen positivity was 34.6%. When compared to negatives, total prostate-specific antigen positive patients had a lower percentage of well-differentiated (P=0.056) and early stage (stages I and II) tumours (P=0.070). However, patients with predominant free prostate-specific antigen, had a higher percentage of well-differentiated (P=0.014) and early stage tumours (P=0.090) than patients with predominant bound prostate-specific antigen. In conclusion, although the sensitivity of free prostate-specific antigen predominancy is low (20%), in distinguishing women with colorectal carcinoma than healthy women, its specificity is high (96.7%). Free prostate-specific antigen predominancy tends to be present in less aggressive tumours. These findings may indicate clinical significance of preoperative measurement of serum total and free prostate-specific antigen in women with colorectal carcinoma.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  • Black MH, Giai M, Ponzone R, Sismondi P, Yu H, Diamandis EP (2000) Serum total and free prostate-specific antigen for breast cancer diagnosis in women. Clin Cancer Res 6: 467–473

    CAS  PubMed  Google Scholar 

  • Borchert GH, Melegos DN, Tomlinson G, Giai M, Roagna R, Ponzone R, Sgro L, Diamandis EP (1997) Molecular forms of prostate-specific antigen in the serum of women with benign and malignant breast diseases. Br J Cancer 76: 1087–1094

    Article  CAS  Google Scholar 

  • Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, Nadler RB (1995) Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274: 1214–1220

    Article  CAS  Google Scholar 

  • Diamandis EP, Yu H (1997) Nonprostatic sources of prostate-specific antigen. Urol Clin N Am 24: 275–282

    Article  CAS  Google Scholar 

  • Fleming ID, Cooper JS, Henson DE, Hutter RVP, Kennedy BJ, Murphy GP, O'Sullivan B, Sobin LH, Yarbro JW (1997) AJCC Cancer Staging Manual. Philadelphia: Lippincott-Raven

  • Henttu P, Liao S, Vinko P (1992) Androgens up-regulate the human prostate-specific antigen messenger ribonucleic acid (mRNA), but down-regulate the prostatic acid phosphatase mRNA in the LNCaP cell line. Endocrinology 130: 766–772

    CAS  PubMed  Google Scholar 

  • Kamoi K, Babaian RJ (1999) Advances in the application of prostate-specific antigen in the detection of early-stage prostate cancer. Semin Oncol 26: 140–149

    CAS  PubMed  Google Scholar 

  • Korenaga D, Orita H, Maekawa S, Hasaka H, Ikeda T, Sugimachi K (1997) Relationship between hormone receptor levels and cell-kinetics in human colorectal cancer. Hepato-Gastroenterol 44: 78–83

    CAS  Google Scholar 

  • Korenaga D, Orita H, Okuyama T, Kinoshita J, Maekawa S, Ikeda T, Sugimachi K (1998) Sex hormone-receptor-negative tumors have a higher proliferative activity than sex hormone-receptor-positive tumors in human adenocarcinomas of the gastrointestinal tract. Jpn J Surg 28: 1007–1014

    CAS  Google Scholar 

  • Levesque MA, Yu H, D'Costa M, Diamandis EP (1995) Prostate specific antigen expression by various tumors. J Clin Lab Anal 9: 123–128

    Article  CAS  Google Scholar 

  • Li W, Ren Y, Mee V, Wong PY (1999) Prostate-specific antigen ratio correlates with aggressiveness of histology grades of prostate cancer. Clin Biochem 32: 31–37

    Article  CAS  Google Scholar 

  • Luke MC, Coffey DS (1994) Human androgen receptor binding to the androgen response element of prostate specific antigen. J Androl 15: 41–51

    CAS  PubMed  Google Scholar 

  • Meggouh F, Lointier P, Pezet D, Saez S (1991) Status of sex steroid hormone receptors in large bowel cancer. Cancer 67: 1964–1970

    Article  CAS  Google Scholar 

  • Romppanen J, Keskikuru R, Kataja V, Eskelinen M, Kosma V-M, Savolainen K, Uusitupa M, Mononen I (1999) Measurement of prostate-specific antigen in detection of benign or malignant breast disease in women. Br J Cancer 79: 1583–1587

    Article  CAS  Google Scholar 

  • Singh S, Sheppard MC, Langman MJS (1993) Sex differences in the incidence of colorectal cancer: an exploration of oestrogen and progesterone receptors. Gut 34: 611–615

    Article  CAS  Google Scholar 

  • Törnblom M, Norming U, Adolfsson J, Becker J, Abrahamsson P-A, Lilja H, Gustafsson O (1999) Diagnostic value of percent free prostate-specific antigen: retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/mL. Urology 53: 945–950

    Article  Google Scholar 

  • van Krieken JHJM (1993) Prostate marker immunoreactivity in salivary gland neoplasms: a rare pitfall in immunohistochemistry. Am J Surg Pathol 17: 410–414

    Article  CAS  Google Scholar 

  • Veltri RW, Miller MC (1999) Free/total PSA ratio improves differentiation of benign and malignant disease of the prostate: critical analysis of two different test populations. Urology 53: 736–745

    Article  CAS  Google Scholar 

  • Yamamoto M, Hibi H, Miyake K (1997) Raised prostate-specific antigen in adenocarcinoma of the colon. Int Urol Nephrol 29: 221–225

    Article  CAS  Google Scholar 

  • Young CYF, Montgomery BT, Andrews PE, Qiu S, Bilhartz DL, Tindall DJ (1991) Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res 51: 3748–3752

    CAS  PubMed  Google Scholar 

  • Yu H, Diamandis EP, Sutherland DJA (1994a) Immunoreactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. Clin Biochem 27: 75–79

    Article  CAS  Google Scholar 

  • Yu H, Diamandis EP, Zarghami N, Grass L (1994b) Induction of prostate specific antigen production by steroids and tamoxifen in breast cancer cell lines. Breast Cancer Res Treat 32: 291–300

    Article  CAS  Google Scholar 

  • Zarghami N, Grass L, Diamandis EP (1997) Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer. Br J Cancer 75: 579–588

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Fifth Department of Surgery, SSK Okmeydanı Training Hospital, PO Box 80434, İstanbul, Turkey

    N Duraker

  2. Third Department of Surgery, SSK Okmeydanı Training Hospital, PO Box 80434, İstanbul, Turkey

    D Can

  3. Department of Nuclear Medicine, SSK Okmeydanı Training Hospital, PO Box 80434, İstanbul, Turkey

    M Parıltı

Authors
  1. N Duraker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D Can
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Parıltı
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N Duraker.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Duraker, N., Can, D. & Parıltı, M. Measurement of serum total and free prostate-specific antigen in women with colorectal carcinoma. Br J Cancer 86, 203–206 (2002). https://doi.org/10.1038/sj.bjc.6600049

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bjc.6600049

Keywords

This article is cited by

Search

Advanced search

Quick links